Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
J Oncol Pharm Pract ; : 10781552231216050, 2023 Nov 19.
Article in English | MEDLINE | ID: mdl-37981866

ABSTRACT

INTRODUCTION: Acute promyelocytic leukemia (APL) is the most malignant form of acute myeloid leukemia (AML) with short survival without treatment. All trans retinoic acid (ATRA) is a vitamin A metabolite and plays an important role in the treatment of APL. Hypercalcemia is a rare side effect of ATRA. CASE REPORT: A 67-year-old female patient was investigated due to widespread bruising and pancytopenia. The patient was diagnosed with APL and remission was achieved by administering idarubicin together with ATRA in the induction treatment. The patient has hypocalcemia due to acquired hypoparathyroidism, and it was observed that the calcium level increased with the initiation of fluconazole 200 mg/day for antifungal prophylaxis together with ATRA in the consolidation treatment. It was observed that the calcium value reached 13 mg/dL by increasing the fluconazole to 400 mg/day treatment dose due to oral mucositis. MANAGEMENT AND OUTCOME: The development of hypercalcemia has been reported in previous case reports when ATRA is used together with voriconazole, fosfluconazole, itraconazole, and posaconazole, which inhibit cytochrome P450 enzymes. In this case, it is the first in the literature that a patient with hypocalcemia due to acquired hypoparathyroidism developed hypercalcemia after fluconazole and ATRA were used together. DISCUSSION: Since hypercalcemia may develop while azole drugs are administered during ATRA treatment, it is important to monitor calcium levels to prevent complications of hypercalcemia.

2.
Transfus Apher Sci ; 56(6): 804-808, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29153305

ABSTRACT

Autologous hematopoietic cell transplantation (AHCT) is an established treatment option for adult patients presenting with multiple myeloma (MM), Hodgkin lymphoma (HL) and various subtypes of non-Hodgkin lymphoma (NHL) in upfront and/or relapsed/refractory disease settings. Although there are recently published consensus guidelines addressing critical issues regarding autologous hematopoietic progenitor cell mobilization (HPCM), mobilization strategies of transplant centers show high variability in terms of routine practice. In order to understand the current institutional policies regarding HPCM in Turkey and to obtain the required basic data for preparation of a national positional statement on this issue, Turkish Hematology Research and Education Group (ThREG) conducted a web-based HPCM survey. The survey was designed to include multiple-choice questions regarding institutional practice of HPCM in adults presenting MM, HL, and NHL. The representatives of 27 adult HCT centers participated to the study. Here we report the results of this survey shedding light on the real-world experience in Turkey in terms of autologous HPCM mobilization strategies in patients presenting with MM and lymphoma.


Subject(s)
Hematopoietic Stem Cell Mobilization/methods , Lymphoma/therapy , Multiple Myeloma/therapy , Transplantation, Autologous/methods , Adult , Female , Humans , Male , Surveys and Questionnaires , Turkey , Young Adult
3.
Turk J Haematol ; 31(2): 121-7, 2014 Jun.
Article in English | MEDLINE | ID: mdl-25035668

ABSTRACT

OBJECTIVE: Venous, arterial, and microcirculatory events are frequently encountered in the clinical course of essential thrombocytosis and polycythemia vera. We aimed to investigate the levels of soluble endothelial protein C receptor (sEPCR) in myeloproliferative diseases to see whether there was a difference between the patients with and without history of thromboembolism. MATERIALS AND METHODS: The study included patients with polycythemia vera (n=12), patients with essential thrombocytosis (n=13), and controls (n=29). In all groups, we measured proteins C and S, antithrombin and sEPCR levels, and plasma concentrations of thrombin-antithrombin complex, prothrombin fragments 1+2, and D-dimer. RESULTS: Comparing the patients with and without history of thromboembolic attack, statistically significant differences were not observed in terms of sEPCR, D-dimer, thrombin-antithrombin complex, prothrombin fragments 1+2, and hematocrit levels (p=0.318, 0.722, 0.743, 0.324, and 0.065, respectively). CONCLUSION: Significant increase in the parameters that reflect activation of coagulation, such as sEPCR, thrombin-antithrombin complex, prothrombin fragments 1+2, and D-dimer, reflects the presence of a basal condition that leads to a tendency toward thrombosis development in ET and PV when compared to healthy controls.

4.
Am J Hematol ; 88(3): 198-200, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23345254

ABSTRACT

Allogeneic stem cell transplantation (allo-SCT) is the only potentially curative treatment for myelodysplastic syndrome (MDS). Recently, hypomethylating agents (HMAs) have been shown to improve survival in patients with high-risk MDS. We conducted a retrospective case-control study to compare survival with these treatment modalities in patients with untreated MDS. Controls were identified using a departmental database and transplant patients were matched in at least three of the following five criteria: year of diagnosis, age, blast percentage, International Prognostic Scoring System cytogenetic risk, and time from diagnosis to treatment. Median overall survival (OS) was 26 and 25 months for, respectively, allo-SCT [(n = 53); range, 2-210 months] and HMA [(n = 40); range, 2-98 months] (P = 0.89). Four-year survival rates were 24 and 23% for allo-SCT patients and the nontransplant cohort, respectively. Patients undergoing allo-SCT after 2000 had longer median OS compared with those transplanted before 2000 (41 versus 7 months, P=0.001). These results would suggest that prospective studies are needed to delineate the timing and efficacy of allo-SCT in the HMA era.


Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Azacitidine/analogs & derivatives , Azacitidine/therapeutic use , Hematopoietic Stem Cell Transplantation , Myelodysplastic Syndromes/therapy , Adult , Aged , Antimetabolites, Antineoplastic/pharmacology , Azacitidine/pharmacology , DNA Modification Methylases/antagonists & inhibitors , Decitabine , Female , Humans , Male , Middle Aged , Myelodysplastic Syndromes/mortality , Myelodysplastic Syndromes/pathology , Research Design , Retrospective Studies , Severity of Illness Index , Survival Rate , Time Factors , Transplantation, Homologous , Treatment Outcome
5.
Biol Blood Marrow Transplant ; 19(2): 214-20, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22982533

ABSTRACT

Risk stratification is important to identify patients with acute myelogenous leukemia (AML) who might benefit from allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission. We retrospectively studied 150 patients with AML and diagnostic cytogenetic abnormalities who underwent myeloablative allo-HSCT while in first complete remission to evaluate the prognostic impact of persistent cytogenetic abnormalities at allo-HSCT. Three risk groups were identified. Patients with favorable/intermediate cytogenetics at diagnosis (n = 49) and patients with unfavorable cytogenetics at diagnosis but without a persistent abnormal clone at allo-HSCT (n = 83) had a similar 3-year leukemia-free survival of 58%-60% despite the higher 3-year relapse incidence (RI) in the latter group (32.3%, versus 16.8% in the former group). A third group of patients with unfavorable cytogenetics at diagnosis and a persistent abnormal clone at allo-HSCT (n = 15) had the worst prognosis, with a 3-year RI of 57.5% and 3-year leukemia-free survival of only 29.2%. These data suggest that patients with AML and unfavorable cytogenetics at diagnosis and a persistent abnormal clone at allo-HSCT are at high risk for relapse after allo-HSCT. These patients should be considered for clinical trials designed to optimize conditioning regimens and/or to use preemptive strategies in the posttransplantion setting aimed at decreasing RI.


Subject(s)
Chromosome Aberrations , Hematopoietic Stem Cell Transplantation/methods , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/surgery , Adult , Disease-Free Survival , Female , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Leukemia, Myeloid, Acute/pathology , Male , Middle Aged , Neoplasm, Residual/genetics , Neoplasm, Residual/pathology , Prognosis , Remission Induction , Transplantation, Homologous
6.
Asian Pac J Allergy Immunol ; 30(2): 162-6, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22830297

ABSTRACT

Immediate hypersensitivity to low molecular weight heparin (LMWH) is rare, and we present here a case with an anaphylaxis-like symptoms to enoxaparin. The diagnosis of hypersensitivity to enoxaparin was confirmed by the clinical picture and positive skin tests. In this case, palmo-plantal itching after application of heparin was an early sign of immediate type hypersensitivity. His skin and provocation tests showed cross-reactivity with other types of LMWHs and un-fractionated heparin (UFH). Fondaparinux and desensitization with UFH were found to be safe alternative treatment options in this patient with heparin allergy.


Subject(s)
Anaphylaxis/drug therapy , Drug Hypersensitivity/drug therapy , Enoxaparin/adverse effects , Heparin/therapeutic use , Hypersensitivity, Immediate/drug therapy , Polysaccharides/therapeutic use , Adult , Anaphylaxis/complications , Anaphylaxis/immunology , Desensitization, Immunologic/methods , Drug Hypersensitivity/complications , Drug Hypersensitivity/immunology , Drug Tolerance , Fondaparinux , Heparin/administration & dosage , Humans , Hypersensitivity, Immediate/complications , Hypersensitivity, Immediate/immunology , Immune Tolerance , Male , Polysaccharides/administration & dosage , Skin Tests
7.
Turk J Haematol ; 29(1): 76-9, 2012 Mar.
Article in English | MEDLINE | ID: mdl-24744628

ABSTRACT

BACKGROUND: Environmental pollution exposes humans to toxic substances. Herein we present 5 family members aged20-54 years that were poisoned by liquid mercury. CASE REPORTS: Case 1 presented to our clinic with cough, fever, and night sweats. The patient had neutropenia, anemia,and pneumonia, rapidly developed acute respiratory distress syndrome (ARDS), and died on day 4 of hospitalization.Her WBC count was 0.4 × 10³ mm-3 (normal range: 4.3-10.3 × 103 mm-3) and Hb was 10.8 g dL-1 (normal range: 11.5-16.0 g dL-1). Case 2 presented with bicytopenia; the leukocyte count was 1.3 × 103 mm-3 (normal range: 4.3-10.3 × 103mm-3) and the PLT count was 88 × 103 mm-3 (normal range: 150-400 × 103 mm-3). Cases 2 and 3 had toxic peripheralneuropathy. The PLT count in case 3 was 123 × 103 mm-3 (normal range: 150-400 × 103 mm-3). Cases 4 and 5 presentedwith fatigue and headache; these 2 patients did not have positive findings, apart from high levels of mercury in theblood. We have written informed consent. CONCLUSION: We think that heavy metal exposure-although rare-should be considered in patients that present withnumerous symptoms involving multiple systems, including the cardiovascular, respiratory, and neurological systems.The present report is unique in that in describes mercury poisoning in 5 members of the same family.

8.
Biol Blood Marrow Transplant ; 17(12): 1841-5, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21684343

ABSTRACT

Complete remission (CR) is the gold standard for assessing outcomes following chemotherapy for acute myelogenous leukemia (AML). "CRp," a response criterion defined as fulfillment of all criteria for CR except platelet count recovery to ≥100 × 10(9)/L, is associated with inferior outcomes following chemotherapy. The prognostic importance of CRp before allogeneic stem cell transplantation (allo-SCT) remains unknown. We analyzed a cohort of AML (n = 334) and myelodysplastic syndrome (MDS; n = 10) patients to determine the prognostic significance of achieving CR versus CRp before allo-SCT. At time of transplantation, 266 patients were in CR (CR1 and ≥CR2) and 78 in CRp (CR1p and ≥CR2p). Median follow-up was 38 months (3-131 months). Overall survival, progression-free survival, and nonrelapse mortality (NRM) were most favorable in patients transplanted in CR (CR1 or ≥CR2) compared with CRp (CR1p or ≥CR2p). Achieving CR is therefore associated with improved posttransplantation outcomes compared with achieving CRp and is a significant prognostic factor that needs to be considered when evaluating AML/MDS patients for clinical trials and allo-SCT.


Subject(s)
Blood Platelets/physiology , Hematopoietic Stem Cell Transplantation/methods , Leukemia, Myeloid, Acute/blood , Leukemia, Myeloid, Acute/surgery , Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/surgery , Transplantation Conditioning/methods , Adolescent , Adult , Aged , Blood Platelets/drug effects , Child , Cohort Studies , Disease-Free Survival , Female , Humans , Leukemia, Myeloid, Acute/drug therapy , Male , Middle Aged , Myelodysplastic Syndromes/drug therapy , Prognosis , Remission Induction , Retrospective Studies , Survival Analysis , Treatment Outcome , Young Adult
10.
Biol Blood Marrow Transplant ; 16(8): 1122-9, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20178853

ABSTRACT

Despite recent advances, multiple myeloma (MM) remains incurable, and most patients eventually develop progressive disease. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a potentially curative option in 10%-20% of patients with relapsed or refractory disease. We evaluated the outcome of patients undergoing allo-HSCT with reduced-intensity conditioning (RIC) for relapsed and/or refractory MM at our institution. The study cohort included 51 patients with heavily pretreated, relapsed MM who underwent RIC allo-HSCT between 1996 and 2006. The median time from diagnosis to allo-HSCT was 34 months, and median follow-up in surviving patients was 27 months (range, 3-98 months). Cumulative transplantation-related mortality at 1 year was 25%. Progression-free survival (PFS) and overall survival (OS) at 2 years were 19% and 32%, respectively. The incidences of grade II-IV acute and chronic graft-versus-host disease were 27% and 47%, respectively. At the time of this analysis, 12 patients (24%) were alive, 7 of whom (14%) were in remission for up to 6 years after allo-HSCT. A lower beta2 microglobulin level (<3.3) and previous autologous HSCT were predictive of lower nonrelapse mortality and longer PFS and OS. Our findings indicate that allo-HSCT with RIC is associated with acceptable toxicity and durable remission and survival in relapsed or refractory MM. The use of RIC allo-HSCT earlier in the course of the disease may offer the greatest benefit.


Subject(s)
Hematopoietic Stem Cell Transplantation/methods , Multiple Myeloma/therapy , Neoplasm Recurrence, Local/therapy , Adult , Aged , Female , Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Male , Middle Aged , Prognosis , Transplantation Conditioning , Treatment Outcome
11.
Curr Opin Oncol ; 20(2): 220-6, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18300773

ABSTRACT

PURPOSE OF REVIEW: The paper compares bone marrow and peripheral blood progenitor cell transplantations in the allogeneic setting. RECENT FINDINGS: Peripheral blood progenitor cell use has emerged as an international standard of care for hematopoietic transplantation. These cells have a different cellular composition including higher numbers of CD34 cells and markedly higher numbers of T lymphocytes. Current data support the general safety of this approach for normal transplant donors. Results consistently indicate more rapid hematopoietic recovery compared with bone marrow transplantation. This may result in improved early survival in adults with high-risk leukemias, but longer follow-up has demonstrated an increased rate of chronic graft-versus-host disease morbidity and mortality which may obviate the long-term benefit. SUMMARY: It is unclear whether peripheral blood progenitor cell or bone marrow transplantation will produce improved disease-free or overall survival. Additional studies with long-term follow-up are necessary to resolve these controversies.


Subject(s)
Bone Marrow Transplantation/methods , Hematopoietic Stem Cell Transplantation/methods , Bone Marrow Transplantation/standards , Hematopoietic Stem Cell Transplantation/standards , Humans
12.
J Natl Med Assoc ; 100(1): 86-90, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18277814

ABSTRACT

Quantitative platelet disorders (i.e., thrombocytosis or thrombocytopenia) may also be associated with qualitative platelet alterations. Clonal thrombocythemia (CT), reactive thrombocytosis (RT), immune thrombocytopenic purpura (ITP), and thrombocytopenia of aplastic pancytopenia (AA) or infiltrative bone marrow disorders represent the major classes of pathological thrombopoiesis. Glycoprotein V may serve as an in vivo marker of platelet activation in thrombotic and hemorrhagic states. The aim of this study was to assess circulating plasma soluble platelet glycoprotein V (sGPV) concentrations in distinct disease states of pathological thrombopoiesis. The whole study group comprised 20 patients with thrombocytopenia, 32 patients with thrombocytosis and 14 healthy adults as the control group. sGPV was significantly increased in the group of thrombocytosis patients in comparison to the thrombocytopenic group and the healthy control groups. When sGPV levels were corrected according to platelet number (sGPV/tr), this ratio was very high in patients with thrombocytopenia compared to patients with thrombocytosis and the control group. Our results suggest that there is an ongoing platelet activation associated with thrombocytosis regardless of its origin is either CT or RT. Therefore, glycoprotein V system may serve to activate residual platelets in thrombocytopenia regardless of its origin is either ITP or AA.


Subject(s)
Platelet Glycoprotein GPIb-IX Complex/analysis , Thrombocytopenia/blood , Thrombocytosis/blood , Adult , Case-Control Studies , Female , Humans , Male , Middle Aged , Solubility
14.
Leuk Res ; 32(3): 495-9, 2008 Mar.
Article in English | MEDLINE | ID: mdl-17706281

ABSTRACT

We describe a 19-year-old male patient with a previous diagnosis of familial Mediterranean fever (FMF), nephrotic syndrome and secondary amyloidosis, who presented with anemia and leukopenia. The bone marrow assessments showed dysplastic precursors including vacuolated myeloid and erythroid precursors and increased proportion of immature cells up to 19%. The patient received erythropoietin and G-CSF for myelodysplastic syndrome (MDS). No response was observed. During his evaluations copper deficiency was detected. One month after oral copper replacement, the peripheral blood counts and bone marrow findings became completely normalized. An evaluation to identify the cause of copper deficiency, revealed intestinal amyloidosis. Based on our experience we recommend serum copper determination in the diagnostic workup of MDS in patients with comorbidities.


Subject(s)
Amyloidosis/complications , Anemia, Refractory, with Excess of Blasts/diagnosis , Bone Marrow/pathology , Copper/deficiency , Myelodysplastic Syndromes/complications , Adult , Anemia, Refractory, with Excess of Blasts/pathology , Familial Mediterranean Fever/complications , Humans , Male
15.
J Natl Med Assoc ; 99(11): 1243-4, 1246-7, 2007 Nov.
Article in English | MEDLINE | ID: mdl-18020099

ABSTRACT

OBJECTIVE: Angiotensin-converting enzyme (ACE) is involved in the control of cellular proliferation. Tumor-associated macrophages promote lymphoma pathogenesis via affecting tumor cell growth and associated survival factors. We assessed ACE expression in the neoplastic lymph node microenvironment of Hodgkin's lymphoma (HL), particularly in macrophages and in nonneoplastic lymphoid tissue. METHODS: Paraffin sections of the lymph nodes from randomly selected 20 HL cases with nodular sclerosing and 20 mixed cellular types were included into the study. Five normal tonsils and five lymph nodes showing reactive lymphoid hyperplasia were used as controls. Immunohistochemistry of lymph node biopsies had been performed with monoclonal antibody against human ACE. Sections were evaluated by two pathologists. RESULTS: ACE-expressing histiocytes were observed in lymph nodes of HL. ACE staining was also observed in the vascular endothelium in all the tissues evaluated. Neoplastic lymphoid tissues and control tissues did not express ACE. CONCLUSION: ACE expression of the lymphoma-associated macrophages in the lymph nodes of HL may represent the point of cross-talk between renin-angiotensin system (RAS) and lymphomagenesis. ACE could serve in the pathobiological function of the tissue-based macrophages in tumorigenesis of HL.


Subject(s)
Acetylcholinesterase/biosynthesis , Hodgkin Disease/immunology , Lymph Nodes/immunology , Macrophages/immunology , Case-Control Studies , Cell Proliferation , Disease Progression , Endothelium , Hodgkin Disease/mortality , Hodgkin Disease/pathology , Humans , Immunohistochemistry
16.
Article in English | MEDLINE | ID: mdl-17907103

ABSTRACT

Local renin-angiotensin system (RAS) may affect leukaemic cell production within the bone marrow microenvironment. Angiotensin-converting enzyme (ACE), renin, and angiotensin could influence leukaemogenesis. In this study, mRNA expressions of the major RAS components (ACE, renin, and angiotensinogen) in K562 human erythroleukaemia cell line have been searched by Real Time quantitative polymerase chain reaction. K562 blasts are multipotential, haematopoietic malignant cells that spontaneously differentiate into recognisable progenitors of the erythrocyte, granulocyte and monocytic series. We observed significant expressions of ACE, renin, and angiotensinogen in K562 leukaemic blast cells. Therefore, K562 human erythroleukaemia cell line may serve as an in vitro model to elucidate the role of RAS in leukaemia and to test the effects of RAS-affecting drugs on leukaemic cellular proliferation.


Subject(s)
Angiotensinogen/genetics , Leukemia, Erythroblastic, Acute/metabolism , Peptidyl-Dipeptidase A/genetics , RNA, Messenger/analysis , Renin/genetics , Cell Line , Computer Systems , Humans , Leukemia, Erythroblastic, Acute/pathology , Polymerase Chain Reaction , Renin-Angiotensin System
17.
J Natl Med Assoc ; 99(1): 57-63, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17304969

ABSTRACT

OBJECTIVES: Local bone marrow renin-angiotensin system (RAS) is an autocrine-paracrine system affecting hematopoiesis. Angiotensin II stimulates the proliferation of bone marrow and umbilical cord blood hematopoietic progenitors. Angiotensin-converting enzyme (ACE) hyperfunction may lead to the acceleration of negative hematopoietic regulator peptide, AcSDKP, metabolism, which in turn lowers its level in the bone marrow microenvironment, finally removing the antiproliferative effect of AcSDKP on the hematopoietic cells and blasts. The aim of this study is therefore to search those major RAS components simultaneously in the leukemic blast cells taken from the bone marrow of patients with acute myeloid leukemia (AML). METHODS: Bone marrow aspiration materials were obtained from 10 patients with AML (8 males, 2 females; median age 48.5 years) and 8 patients with nonmalignant hematological disorders (6 males, 2 females; median age 45 years). EDTA-treated bone marrow samples were stored at -70 degrees C until analysis. Total RNA was extracted from 200-microl bone marrow samples by High Pure RNA Isolation Kit. RESULTS: The medians of expression ratios of AML patient samples have been found 0.736 (IQR 1.359), 0.540 (IQR 0.725), and 0.075 (IQR 0.002) for ACE, ANG and REN genes, respectively. All three gene expressions were found to be significantly higher in the bone marrow samples of AML patients. CONCLUSION: In this study, the expression of the mRNAs of the major RAS components-namely ACE, renin and angiotensinogen-in human bone marrow samples were quantified by reverse transcription-polymerase chain reaction (RT-PCR) to confirm the presence of the local bone marrow RAS. Elucidation of the pathological activity of the local RAS-mediated regulation of the leukemogenesis is both pathobiologically and clinically important, since the angiotensin peptides represent a molecular target in the disease management.


Subject(s)
Bone Marrow/chemistry , Leukemia, Myeloid/physiopathology , Renin-Angiotensin System/physiology , Acute Disease , Angiotensins/genetics , Gene Expression Regulation, Leukemic , Oligopeptides/analysis , Peptidyl-Dipeptidase A/genetics , Renin/genetics
19.
Turk J Haematol ; 24(4): 177-80, 2007 Dec 05.
Article in English | MEDLINE | ID: mdl-27263958

ABSTRACT

Extramedullary hematopoiesis (EMH) may uncommonly develop during the course of polycythemia vera (PV). We herein present a 57-year-old patient with spinal epidural EMH that developed during the complicated course of PV and his outcome under different treatment modalities including hydroxyurea, 32P, radiotherapy and surgery.

20.
Hematology ; 11(2): 105-7, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16753850

ABSTRACT

Extramedullary recurrences with or without bone marrow involvement are reported in up to a half of leukemic relapses after BMT. Our report describes a case of an extramedullary recurrence and breast relapse after second-allografting in a female patient with Ph+-acute lymphoblastic leukemia (ALL), occurring when there was active hepatic GHVD. This case illustrates the complex relationship between graft-versus-host disease (GVHD) and graft-versus-leukemia since she had no evidence of leukemia in her marrow demonstrating 100% full-donor chimerism while she had ALL relapse in her breast.


Subject(s)
Breast/pathology , Graft vs Host Disease , Leukemic Infiltration/pathology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Female , Graft vs Host Disease/complications , Graft vs Host Disease/pathology , Hematopoietic Stem Cell Transplantation , Humans , Liver/pathology , Middle Aged , Philadelphia Chromosome , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Preleukemia/therapy , Remission Induction
SELECTION OF CITATIONS
SEARCH DETAIL
...